Altanine, Inc., a pharmaceutical company specializing in proprietary drug delivery technologies for high-growth therapeutic areas, has appointed Charles J. Andres, Ph.D., J.D., as its new Chief Executive Officer. Dr. Andres is a 2010 alumnus of Catholic Law.

Dr. Andres brings extensive expertise in intellectual property strategy, regulatory affairs, and life science discovery and development. His appointment strengthens Altanine’s ability to advance its mission to improve patient outcomes through proprietary drug delivery innovations in high-growth therapeutic markets.

“Charlie is a visionary leader with a profound understanding of the pharmaceutical landscape,” said George Hornig, Chairman of the Board of Altanine. “His expertise in new drug development, intellectual property, and regulatory strategy, combined with his scientific background, makes him uniquely qualified to lead Altanine as we continue to revolutionize drug delivery technologies and expand our impact across key therapeutic areas.”

Click here to view the full press release.